← All trials
NCT07028801
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2025
- Primary completion
- Sep 30, 2025
- Completion date
- Mar 31, 2026
- First posted
- Jun 19, 2025
- Last posted
- Jun 19, 2025
- Enrollment
- 3000
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AIM Therapeutics Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.